Tyrosine kinase inhibitors (TKIs) which target angiogenesis are promising treatments for
patients with metastatic medullary and differentiated thyroid cancers. Sorafenib, sunitinib …

Systemic chemotherapies for advanced or metastatic thyroid carcinomas have been of only
limited effectiveness. For patients with differentiated or medullary carcinomas unresponsive …

Abstract Objective Tyrosine kinase inhibitors (TKIs) are used to treat patients with advanced
thyroid cancers. We retrospectively investigated the efficacy of TKIs administered outside of …

The knowledge on thyroid cancer biology has grown over the past decade. Thus, diagnostic
and therapeutic strategies to manage thyroid cancer are rapidly evolving. With new insights …

The tyrosine kinase inhibitors (TKIs) sorafenib, lenvatinib, vandetanib, and cabozantinib are
currently used for thyroid cancer treatment; however, the differences in their clinical efficacy …

Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC),
sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary …

Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising
incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with …

Introduction: Patients with progressive, metastatic, RAI-refractory differentiated thyroid
cancer (DTC), as well as patients with advanced medullary (MTC) and anaplastic thyroid …

Medical oncologists have traditionally had little to offer patients with metastatic radioactive
iodine-resistant thyroid cancer. The 3-year survival rate of patients with differentiated thyroid …

Context Many tyrosine kinase inhibitors (TKIs) have been studied in patients with thyroid
carcinoma (TC). However, the effect and toxicity of various TKIs in differentiated TC (DTC) …